|
|
October 13-14, 1995
Brief Overview
This conference built on one held in July 1993, reported in 5(2) Risk: Health, Safety & Environment (Spring 1994). An annotated index with brief introductions -- as well as the text of papers from both conferences are all online.
The 1993 conference explored the effects of intellectual property and federal technology transfer laws on maximizing the return from federally-sponsored genome research. The 1995 conference examined how the prospects for returns from genome research will be further affected by other forms of legal regulation (including the tort system) -- as well as the relationships between several kinds of regulation.
* Overview of Legal & Ethical Issues
* Promoting Risk Management Objectives
* Promoting Genome Innovation While Managing Risks
* Implications?
* Sponsors & Co-chairs
Overview of Legal & Ethical Issues
* Professor Karl Jorda, Moderator
[Click here to see Professor Jorda's biographical listing at this web site -- and select "go back" to return.]
* Dr. Elaine Draper, Social Issues of Genome Innovation and Intellectual Property
Dr. Draper is a Professor of Sociology at the University of Southern California and author of Risky Business: Genetic Testing and Exclusionary Practices in the Hazardous Workplace (reviewed in Risk).
* Dr. Kate Murashige, Esq., Genome Research and Traditional Intellectual Property -- A Bad Fit?
Dr. Murashige, in addition to being a lawyer, has a Ph.D. (Chemistry) from UCLA. She is is a partner in Morrison & Foerster in Washington DC.
* Professor Phillip K. Russell, M.D., Development of Vaccines to Meet Public Health Needs: Incentives and Obstacles
Dr. Russell is a Professor in the Department of International Health at the Johns Hopkins University School of Hygiene and Public Health.
* Brian C. Cunningham, Esq., Implications of the Human Genome Project at the Intersection of Patent Law and FDA Regulation
Mr. Cunningham is a partner in Cooley, Godward, Castro, Huddleson & Tatum in Palo Alto CA and former General Counsel of Genetech, Inc.
Promoting Risk Management Objectives
* Karin Gregory, Esq., How Premarket Testing Obligations Affect Incentives to Innovate
Ms. Gregory is a health care and biotechnology business consultant and attorney practicing in Boston.
* Jeffrey H. Gibbs, Esq.
Marketing Issues: Government Regulation and Torts
Mr. Gibbs is a partner in Hyman, Phelps & McNamarra, Washington DC, and has written frequently on FDA regulation and product liability.
Promoting Genome Innovation
While Managing Risks
* Dr. Michael Connolly, Regulation and the Development of Bioremediation
Dr. Connolly is a clerk at Nixon, Hargrave, Devans & Doyle, Rochester NY and a student at Cornell Law School.
*Dr. Robert Benson, Esq., A View from the Hotseat
Dr. Benson is Vice President, General Counsel and Secretary of Human Genome Sciences. Besides being a lawyer, he has a Ph.D. (Molecular Biology) from the University of Florida.
Implications?
Open discussion of emerging themes from the perspective of:
*Overall public policy
*Firms engaged in genome research and innovation
Sponsors and Co-chairs
*Jointly sponsored by the - http://www.er.doe.gov/production/oher/hug_top.html - Human Genome Program of the U.S. Department of Energy; Franklin Pierce Law Center; Nixon, Hargrave, Devans and Doyle (Rochester, NY) and Human Genome Sciences, Inc.
* Co-chaired by Professor Thomas Field (Franklin Pierce) and Gianna Julian-Arnold, Esq. (Nixon, Hargrave... during early planning).
Risk Articles Index
More information about the published proceedings
General information about the Human Genome Project
General information about intellectual property
Modified 11/16/96
Franklin Pierce Law Center
Two White Street • Concord, NH 03301 • 603.228.1541
© 2002-2007 Franklin Pierce Law Center. All rights reserved.
|
